CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 17, 2006--Idera Pharmaceuticals, Inc. (AMEX: IDP - News) today announced the granting of patents in Europe (EU 1,278,761) and Australia (AU 2001257366) on immune modulatory oligonucleotides (IMO(TM)) that target Toll-like Receptors (TLRs). The claims of these patents cover both compositions of matter and methods of use for a broad range of IMOs. The composition of matter claims include synthetic immune stimulatory motifs, such as cytosine and 7-deazaguanosine, and structural modifications to the oligonucleotides that affect their immunological activity. Similar patents are pending in the United States.
